Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492426 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
A Phase 3 study of Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT01492426 is a Phase 3 study of Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 605 participants, below the 1,884-participant average among 106 other Hepatitis C trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT01492426, a Phase 3 study of Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Peginterferon alfa-2a
- DRUG Telaprevir
Study Locations (20)
North Carolina
- University Of North Carolina At Chapel Hill School Of Med - Chapel Hill
- Carolinas Medical Center - Charlotte
- Duke University Medical Center - Durham
California
- Va Long Beach Healthcare System - Long Beach
- Medical Associates Research Group - San Diego
Georgia
- Atlanta Medical Center - Atlanta
- Gastrointestinal Specialists Of Georgia - Marietta
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
Maryland
- University Of Maryland - Baltimore
- Johns Hopkins University - Lutherville
Alabama
- The Kirklin Clinic - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Connecticut
- Yale University School Of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492426
The ClinicalTrials.gov registry entry for NCT01492426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,884-participant average among 106 other Hepatitis C trials with a reported enrollment target (68% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 4 interventions - of which Ribavirin is the first listed.
NCT01492426 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01492426 about?
NCT01492426 is a clinical study titled "Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection". The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
What is the current status of trial NCT01492426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2012-01. Estimated completion is 2014-03.
What conditions does trial NCT01492426 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01492426?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Peginterferon alfa-2a (DRUG), Telaprevir (DRUG).
Who is sponsoring clinical trial NCT01492426?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01492426 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
COMPLETED · Phase 3
-
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
-
Hepatitis C Antiviral Resistance in African-Americans
COMPLETED · Phase 3
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.